Alan M. Seddon

984 total citations
40 papers, 783 citations indexed

About

Alan M. Seddon is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan M. Seddon has authored 40 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan M. Seddon's work include HER2/EGFR in Cancer Research (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (6 papers). Alan M. Seddon is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Colorectal Cancer Treatments and Studies (8 papers) and Lung Cancer Treatments and Mutations (6 papers). Alan M. Seddon collaborates with scholars based in United Kingdom, United States and Austria. Alan M. Seddon's co-authors include Helmout Modjtahedi, Andrey V. Karlyshev, Sharadah Essapen, Nikolaos Ioannou, Angus Dalgleish, David Mackintosh, G. Hossein Ashrafi, Polly Hayes, Angela J. Davies and David Wertheim and has published in prestigious journals such as PLoS ONE, Applied and Environmental Microbiology and Scientific Reports.

In The Last Decade

Alan M. Seddon

39 papers receiving 765 citations

Peers

Alan M. Seddon

ONCOL

PRM

ECOLO

Angelo Ferrari Italy

H. Becker Germany

Joseph M. Petroziello United States

Mauricio Salcedo Mexico

Zhen Qin China

Ellen J. Beswick United States

Laura Masini Italy

Matija Rijavec Slovenia

Garry M. Marley United States

Kouhei Sakai Japan

Angelo Ferrari Italy

Alan M. Seddon

181 ×0.7

271 ×1.1

ONCOL

52 ×0.4

241 ×2.0

PRM

33 ×0.3

ECOLO

Citations per year, relative to Alan M. Seddon Alan M. Seddon (= 1×) peers Angelo Ferrari

Countries citing papers authored by Alan M. Seddon

Since Specialization

Citations

This map shows the geographic impact of Alan M. Seddon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan M. Seddon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan M. Seddon more than expected).

Fields of papers citing papers by Alan M. Seddon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan M. Seddon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan M. Seddon. The network helps show where Alan M. Seddon may publish in the future.

Co-authorship network of co-authors of Alan M. Seddon

This figure shows the co-authorship network connecting the top 25 collaborators of Alan M. Seddon. A scholar is included among the top collaborators of Alan M. Seddon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan M. Seddon. Alan M. Seddon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seddon, Alan M., et al.. (2024). The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells. World Journal of Oncology. 15(2). 192–208. 4 indexed citations

Seddon, Alan M., et al.. (2023). The Co-expression of HER Family Members and CD109 is common in Pancreatic Cancer.. Medical Research Archives. 11(11). 2 indexed citations

Seddon, Alan M., et al.. (2023). Detection of high-risk Human Papillomavirus in prostate cancer from a UK based population. Scientific Reports. 13(1). 7633–7633. 12 indexed citations

Essapen, Sharadah, et al.. (2018). Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. Oncotarget. 9(28). 19662–19674. 13 indexed citations

Seddon, Alan M., et al.. (2017). Potential probiotic-associated traits revealed from completed high quality genome sequence of Lactobacillus fermentum 3872. Standards in Genomic Sciences. 12(1). 19–19. 21 indexed citations

Seddon, Alan M., et al.. (2017). The hidden perils of read mapping as a quality assessment tool in genome sequencing. Scientific Reports. 7(1). 43149–43149. 5 indexed citations

Ashrafi, G. Hossein, et al.. (2017). Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Scientific Reports. 7(1). 3964–3964. 68 indexed citations

Ioannou, Nikolaos, Alan M. Seddon, Angus Dalgleish, et al.. (2016). Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal of Oncology. 48(3). 908–918. 23 indexed citations

Seddon, Alan M., et al.. (2016). YPTB3816 of Yersinia pseudotuberculosis strain IP32953 is a virulence-related metallo-oligopeptidase. BMC Microbiology. 16(1). 282–282. 1 indexed citations

10.

Essapen, Sharadah, et al.. (2015). Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer. 113(7). 1010–1019. 20 indexed citations

11.

Seddon, Alan M., et al.. (2015). Lactobacillus fermentum 3872 genome sequencing reveals plasmid and chromosomal genes potentially involved in a probiotic activity. FEMS Microbiology Letters. 362(11). 19 indexed citations

12.

Seddon, Alan M., et al.. (2014). A negative effect of Campylobacter capsule on bacterial interaction with an analogue of a host cell receptor. BMC Microbiology. 14(1). 141–141. 11 indexed citations

13.

Ioannou, Nikolaos, Alan M. Seddon, Angus Dalgleish, David Mackintosh, & Helmout Modjtahedi. (2013). Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer. 13(1). 41–41. 43 indexed citations

14.

Modjtahedi, Helmout, Ruth S. Kirk, Alan M. Seddon, et al.. (2012). Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer. 106(5). 883–888. 10 indexed citations

15.

Ioannou, Nikolaos, Angus Dalgleish, Alan M. Seddon, et al.. (2011). Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer. 105(10). 1554–1562. 64 indexed citations

16.

Hayes, Polly, Nico J. Smit, Alan M. Seddon, David Wertheim, & Angela J. Davies. (2006). A new fish haemogregarine from South Africa and its suspected dual transmission with trypanosomes by a marine leech. Folia Parasitologica. 53(4). 241–248. 32 indexed citations

17.

Meimaridou, Eirini, Jake Jacobson, Alan M. Seddon, et al.. (2005). Crystal and microparticle effects on MDCK cell superoxide production: oxalate-specific mitochondrial membrane potential changes. Free Radical Biology and Medicine. 38(12). 1553–1564. 28 indexed citations

18.

McNaughton, Lars R., et al.. (2002). The Acute 1-Week Effects of the Zone Diet on Body Composition, Blood Lipid Levels, and Performance in Recreational Endurance Athletes. The Journal of Strength and Conditioning Research. 16(1). 50–50. 18 indexed citations

19.

Bearn, Philip, Kathleen M. Miller, Helen A. Bull, et al.. (1992). An immunohistochemical study of mesothelial cell seeding for knitted Dacron.. PubMed. 73(6). 801–8. 6 indexed citations

20.

Ville, A.E. La, Alan M. Seddon, M Shaikh, et al.. (1989). Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain. Atherosclerosis. 78(2-3). 205–210. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact